Lan A J, Colford J M, Colford J M
University of California, San Diego, California, USA.
Pediatrics. 2000 Feb;105(2):E19. doi: 10.1542/peds.105.2.e19.
The recommended dosing frequency of oral penicillin for the treatment of acute streptococcal tonsillopharyngitis has long been 3 to 4 times daily. In 1994, treatment guidelines included twice-daily (BID) dosing for the first time, a recommendation that could significantly increase the ease of compliance. This meta-analysis was performed to determine whether overall cure rates differed between BID or once-daily (QD) versus more frequent dosing schedules in the treatment of streptococcal tonsillopharyngitis.
Candidate studies for this meta-analysis included all clinical trials of therapy for streptococcal tonsillopharyngitis published through August 1998 and identified using Medline, Dissertation Abstracts, conference proceedings, and bibliographies of all retrieved articles.
A study was eligible for inclusion if it was a randomized clinical trial that compared the efficacies of different dosing frequencies of 10-day penicillin or amoxicillin in the treatment of streptococcal tonsillopharyngitis. Of the 30 articles initially identified, 6 studies met eligibility criteria.
The measure of interest was the difference in proportion cured between the BID or QD dosing group and the comparison group with more frequent dosing.
The results of this analysis suggest that BID dosing of 10-day penicillin is as efficacious as more frequent dosing regimens in the treatment of streptococcal tonsillopharyngitis. This result also holds true in a subgroup analysis confined to pediatric cases and does not vary with total daily dose of the regimen. QD dosing of penicillin is associated with a cure rate that is 12 percentage points lower than more frequent dosing (95% confidence interval: 3-21). In contrast, this decreased efficacy is not found with QD dosing of amoxicillin.
This meta-analysis supports current recommendations for BID dosing of penicillin in treating streptococcal tonsillopharyngitis. QD penicillin is associated with decreased efficacy and should not be used. Simplified regimens of amoxicillin of shorter duration or of less frequent dosing should be further investigated.
长期以来,口服青霉素治疗急性链球菌性扁桃体咽炎的推荐给药频率一直是每日3至4次。1994年,治疗指南首次纳入了每日两次(BID)给药方案,该推荐可显著提高依从性。进行这项荟萃分析以确定在治疗链球菌性扁桃体咽炎时,每日两次或每日一次(QD)给药方案与更频繁给药方案的总体治愈率是否存在差异。
这项荟萃分析的候选研究包括截至1998年8月发表的所有关于链球菌性扁桃体咽炎治疗的临床试验,通过医学文献数据库(Medline)、论文摘要、会议论文集以及所有检索文章的参考文献进行识别。
若一项研究为随机临床试验,比较了10天青霉素或阿莫西林不同给药频率在治疗链球菌性扁桃体咽炎中的疗效,则该研究符合纳入标准。在最初识别的30篇文章中,有6项研究符合纳入标准。
关注的指标是每日两次或每日一次给药组与更频繁给药对照组之间的治愈比例差异。
该分析结果表明,10天青霉素每日两次给药在治疗链球菌性扁桃体咽炎方面与更频繁给药方案同样有效。这一结果在仅限于儿科病例的亚组分析中也成立,且不随给药方案的每日总剂量而变化。青霉素每日一次给药的治愈率比更频繁给药低12个百分点(95%置信区间:3 - 21)。相比之下,阿莫西林每日一次给药未发现疗效降低。
这项荟萃分析支持目前关于青霉素每日两次给药治疗链球菌性扁桃体咽炎的推荐。每日一次青霉素给药疗效降低,不应使用。应进一步研究疗程更短或给药频率更低的简化阿莫西林给药方案。